Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Maxim Group
Maxim Group assumed coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $17.00 price target on the stock. Several other research firms have also recently commented on NVCT. Laidlaw began coverage on shares of […]
Maxim Group assumed coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $17.00 price target on the stock. Several other research firms have also recently commented on NVCT. Laidlaw began coverage on shares of […]
